The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses individualized holding and bridging therapy before BCMA-directed CAR T-cell therapy in patients with multiple myeloma. She highlights how treatment can be tailored to patient characteristics, tumor burden, and cytogenetic abnormalities, emphasizing that achieving a deeper response before infusion was associated with lower toxicity. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Individualized bridging or holding and bridging therapy means that you have to choose a bridging regimen depending on the patient’s characteristics, for example, extramedullary disease, prior lines of therapy, and the most important part is that you bridge until a deep response, because what we could see is that the deeper the response, the lower the toxicities, and even the difference between a PR and a VGPR makes a significant difference...
Individualized bridging or holding and bridging therapy means that you have to choose a bridging regimen depending on the patient’s characteristics, for example, extramedullary disease, prior lines of therapy, and the most important part is that you bridge until a deep response, because what we could see is that the deeper the response, the lower the toxicities, and even the difference between a PR and a VGPR makes a significant difference. So individualized, like I said, patient characteristics, for example, with the translocation t(11;14), we try to use a venetoclax-based regimen. Patient with a high tumor burden, we try to use intensive therapy, especially chemotherapy and polychemotherapy. And I think there’s not the right bridging regimen, but there’s the right regimen for the patient. And what we did is that if the patient doesn’t respond well we change it so the depth of response at the end is the most important part.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
